Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
exenatide
sitagliptin
placebo
placebo
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring diabetes, exenatide, sitagliptin, Amylin, Lilly, metformin, thiazolidinedione
Eligibility Criteria
Inclusion Criteria:
- Have type 2 diabetes
- Has HbA1c 7.0% to 11.0%, at or within 4 weeks prior to Visit 1.
- Have a fasting glucose concentration <280 mg/dL at Visit 1
- Have been treated with a stable dose of immediate or extended release metformin for at least 60 days prior to screening OR TZD (rosiglitazone or pioglitazone) for at least 120 days prior to screening.
- Are between 18 and 70 years of age, inclusive.
- Have body mass index ≥25 kg/m2 and ≤45 kg/m2.
- Have a history of stable body weight (not varying by >10% for at least 3 months prior to screening).
- Can swallow oral study drug capsule, without splitting or crushing.
Exclusion Criteria:
Female patients of childbearing potential (not surgically sterilized and between menarche and 1 year postmenopause) who meet any of the following criteria:
- Are breastfeeding.
- Test positive for pregnancy at the time of screening.
- Intend to become pregnant during the study.
- Have not practiced a reliable method of birth control (for example, use of oral contraceptives or Norplant®; diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam; intrauterine devices; partner with vasectomy; or abstinence) for 3 months prior to screening.
Treated with any of the following medications:
- Insulin, exenatide, pramlintide, sulfonylureas or meglitinides within 3 months of screening
- Alpha-glucosidase inhibitor within 2 months of screening.
- Drugs that directly affect gastrointestinal motility, including, but not limited to metoclopramide, cisapride, and chronic macrolide antibiotics.
- Use of a drug for weight loss (for example, prescription drugs such as orlistat, sibutramine, phentermine, or similar over-the-counter medications) within 3 months prior to Visit 1.
- Systemic corticosteroids by oral, intravenous, or intramuscular route within 2 months of screening.
- Have a history of renal transplantation or are currently receiving renal dialysis.
- Have obvious clinical signs or symptoms of liver disease or acute or chronic hepatitis.
- Have known active proliferative retinopathy or macular edema expected to need treatment with focal photocoagulation within 3 months.
- Have an active or untreated malignancy, or have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years.
- Have had organ transplantation.
- Have received GLP-1 analogs other than exenatide or DPP-4 inhibitors within the previous 3 months.
- Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
Sites / Locations
- Research Site
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Sequence A
Sequence B
Arm Description
Outcomes
Primary Outcome Measures
Change in Time-averaged Glucose During a 24 Hour Period
Change in time-averaged glucose during a 24-hour period from baseline to endpoint (i.e., time-averaged glucose over 24 hours at endpoint minus time-averaged glucose over 24 hours at baseline).
Secondary Outcome Measures
Change in Two-hour Postprandial Glucose After the Morning Meal
Change in 2 hour post-prandial glucose after the morning meal from baseline to endpoint (i.e., glucose level 2 hours after the morning meal at baseline minus glucose level 2 hours after the morning meal at endpoint)
Change in Fasting Blood Glucose After the Morning Meal
Change in fasting blood glucose after the morning meal from baseline to endpoint (i.e., fasting blood glucose after the morning meal at baseline minus fasting blood glucose after the morning meal at endpoint)
Change in Postprandial Glucagon Area Under the Concentration-time Curve (AUC) After the Morning Meal
Change in Postprandial Glucagon AUC after the morning meal (t=0 to 4 hours) (i.e., Glucagon AUC over the first 4 hours following the morning meal at baseline minus glucagon AUC over the first 4 hours following the morning meal at endpoint)
Change in Postprandial Glucagon AUC Excursion After the Morning Meal
Change in postprandial glucagon AUC excursion after the morning meal (t=0 to 4 hours) (i.e., glucagon AUC excursion for 4 hours following the morning meal at baseline minus glucagon AUC excursion for 4 hours following the morning meal at endpoint)
Change in Postprandial Triglyceride AUC After the Morning Meal
Change in postprandial triglyceride AUC after the morning meal (t=0 to 4 hours) (i.e., postprandial triglyceride AUC after the morning meal at baseline minus postprandial triglyceride AUC after the morning meal at endpoint)
Change in Postprandial Triglyceride AUC Excursion After the Morning Meal
Change in postprandial triglyceride AUC excursion after the morning meal (t=0 to 4 hours) (i.e., postprandial triglyceride AUC excursion after the morning meal at baseline minus postprandial triglyceride AUC excursion after the morning meal at endpoint)
Change in Postprandial C-peptide AUC After the Morning Meal
Change in postprandial C-peptide AUC after the morning meal (t=0 to 4 hours) (i.e., postprandial C-peptide AUC after the morning meal at baseline minus postprandial C-peptide AUC after the morning meal at endpoint)
Change in Postprandial C-peptide AUC Excursion After the Morning Meal
Change in Postprandial C-peptide AUC excursion after the morning meal (t=0 to 4 hours) (i.e., postprandial C-peptide AUC excursion after the morning meal at baseline minus postprandial C-peptide AUC excursion after the morning meal at endpoint)
Change in Postprandial Insulin AUC After the Morning Meal
Change in postprandial insulin AUC after the morning meal (t=0 to 4 hours) (i.e., postprandial insulin AUC after the morning meal at baseline minus postprandial insulin AUC after the morning meal at endpoint)
Change in Postprandial Insulin AUC Excursion After the Morning Meal
Change in Postprandial insulin AUC excursion after the morning meal (t=0 to 4 hours) (i.e., postprandial insulin AUC excursion after the morning meal at baseline minus postprandial insulin AUC excursion after the morning meal at endpoint)
Change in Postprandial Active GLP-1 AUC After the Morning Meal
Change in Postprandial active GLP-1 AUC after the morning meal (t=0 to 4 hours) (i.e., postprandial active GLP-1 AUC after the morning meal at baseline minus postprandial active GLP-1 AUC after the morning meal at endpoint)
Change in Postprandial Active GLP-1 AUC Excursion After the Monrning Meal
Change in Postprandial active GLP-1 AUC excursion after the morning meal (t=0 to 4 hours) (i.e., postprandial active GLP-1 AUC excursion after the morning meal at baseline minus postprandial active GLP-1 AUC excursion after the morning meals at endpoint)
Percentage of Patients Experiencing Hypoglycemia (Baseline to Week 4)
Percentage of patients experiencing minor hypoglycemia with a confirmed glucose <54mg/dL
Episodes of Hypoglycemia (Baseline to Week 4)
Number of episodes of hypoglycemia experienced during the first 4 weeks of the study
Percentage of Patients Experiencing Hypoglycemia (Week 4 to Week 8)
Percentage of patients experiencing minor hypoglycemia with a confirmed glucose <54mg/dL
Episodes of Hypoglycemia (Week 4 to Week 8)
Number of episodes of hypoglycemia experienced between week 4 and week 8 of the study
Percentage of Patients Experiencing Hypoglycemia (Overall)
Percentage of patients experiencing minor hypoglycemia with a confirmed glucose <54mg/dL
Episodes of Hypoglycemia (Overall)
Number of episodes of hypoglycemia experienced overall during the study
Full Information
NCT ID
NCT00729326
First Posted
August 4, 2008
Last Updated
March 20, 2015
Sponsor
AstraZeneca
Collaborators
Eli Lilly and Company
1. Study Identification
Unique Protocol Identification Number
NCT00729326
Brief Title
Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione
Official Title
Comparison of the Effect of Exenatide vs. Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione
Study Type
Interventional
2. Study Status
Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
August 2008 (undefined)
Primary Completion Date
October 2009 (Actual)
Study Completion Date
October 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca
Collaborators
Eli Lilly and Company
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study is designed to compare the short-term effects and mechanisms of action of exenatide with those of sitagliptin when either is added to an oral agent(metformin or a thiazolidinedione [TZD]) in adult patients with type 2 diabetes mellitus(T2DM) with inadequate glycemic control.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
diabetes, exenatide, sitagliptin, Amylin, Lilly, metformin, thiazolidinedione
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
83 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Sequence A
Arm Type
Experimental
Arm Title
Sequence B
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
exenatide
Other Intervention Name(s)
Byetta
Intervention Description
subcutaneous injection (5mcg or 10mcg), twice a day
Intervention Type
Drug
Intervention Name(s)
sitagliptin
Other Intervention Name(s)
Januvia
Intervention Description
oral administration (100mg), once a day in the morning
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
subcutaneous injection (5mcg or 10mcg), twice a day
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
oral administration (100mg), once a day in the morning
Primary Outcome Measure Information:
Title
Change in Time-averaged Glucose During a 24 Hour Period
Description
Change in time-averaged glucose during a 24-hour period from baseline to endpoint (i.e., time-averaged glucose over 24 hours at endpoint minus time-averaged glucose over 24 hours at baseline).
Time Frame
baseline and 8 Weeks
Secondary Outcome Measure Information:
Title
Change in Two-hour Postprandial Glucose After the Morning Meal
Description
Change in 2 hour post-prandial glucose after the morning meal from baseline to endpoint (i.e., glucose level 2 hours after the morning meal at baseline minus glucose level 2 hours after the morning meal at endpoint)
Time Frame
baseline and 8 Weeks
Title
Change in Fasting Blood Glucose After the Morning Meal
Description
Change in fasting blood glucose after the morning meal from baseline to endpoint (i.e., fasting blood glucose after the morning meal at baseline minus fasting blood glucose after the morning meal at endpoint)
Time Frame
baseline and 8 Weeks
Title
Change in Postprandial Glucagon Area Under the Concentration-time Curve (AUC) After the Morning Meal
Description
Change in Postprandial Glucagon AUC after the morning meal (t=0 to 4 hours) (i.e., Glucagon AUC over the first 4 hours following the morning meal at baseline minus glucagon AUC over the first 4 hours following the morning meal at endpoint)
Time Frame
baseline and 8 Weeks
Title
Change in Postprandial Glucagon AUC Excursion After the Morning Meal
Description
Change in postprandial glucagon AUC excursion after the morning meal (t=0 to 4 hours) (i.e., glucagon AUC excursion for 4 hours following the morning meal at baseline minus glucagon AUC excursion for 4 hours following the morning meal at endpoint)
Time Frame
baseline and 8 Weeks
Title
Change in Postprandial Triglyceride AUC After the Morning Meal
Description
Change in postprandial triglyceride AUC after the morning meal (t=0 to 4 hours) (i.e., postprandial triglyceride AUC after the morning meal at baseline minus postprandial triglyceride AUC after the morning meal at endpoint)
Time Frame
baseline and 8 Weeks
Title
Change in Postprandial Triglyceride AUC Excursion After the Morning Meal
Description
Change in postprandial triglyceride AUC excursion after the morning meal (t=0 to 4 hours) (i.e., postprandial triglyceride AUC excursion after the morning meal at baseline minus postprandial triglyceride AUC excursion after the morning meal at endpoint)
Time Frame
baseline and 8 Weeks
Title
Change in Postprandial C-peptide AUC After the Morning Meal
Description
Change in postprandial C-peptide AUC after the morning meal (t=0 to 4 hours) (i.e., postprandial C-peptide AUC after the morning meal at baseline minus postprandial C-peptide AUC after the morning meal at endpoint)
Time Frame
baseline and 8 Weeks
Title
Change in Postprandial C-peptide AUC Excursion After the Morning Meal
Description
Change in Postprandial C-peptide AUC excursion after the morning meal (t=0 to 4 hours) (i.e., postprandial C-peptide AUC excursion after the morning meal at baseline minus postprandial C-peptide AUC excursion after the morning meal at endpoint)
Time Frame
baseline and 8 Weeks
Title
Change in Postprandial Insulin AUC After the Morning Meal
Description
Change in postprandial insulin AUC after the morning meal (t=0 to 4 hours) (i.e., postprandial insulin AUC after the morning meal at baseline minus postprandial insulin AUC after the morning meal at endpoint)
Time Frame
baseline and 8 Weeks
Title
Change in Postprandial Insulin AUC Excursion After the Morning Meal
Description
Change in Postprandial insulin AUC excursion after the morning meal (t=0 to 4 hours) (i.e., postprandial insulin AUC excursion after the morning meal at baseline minus postprandial insulin AUC excursion after the morning meal at endpoint)
Time Frame
baseline and 8 Weeks
Title
Change in Postprandial Active GLP-1 AUC After the Morning Meal
Description
Change in Postprandial active GLP-1 AUC after the morning meal (t=0 to 4 hours) (i.e., postprandial active GLP-1 AUC after the morning meal at baseline minus postprandial active GLP-1 AUC after the morning meal at endpoint)
Time Frame
baseline and 8 Weeks
Title
Change in Postprandial Active GLP-1 AUC Excursion After the Monrning Meal
Description
Change in Postprandial active GLP-1 AUC excursion after the morning meal (t=0 to 4 hours) (i.e., postprandial active GLP-1 AUC excursion after the morning meal at baseline minus postprandial active GLP-1 AUC excursion after the morning meals at endpoint)
Time Frame
baseline and 8 Weeks
Title
Percentage of Patients Experiencing Hypoglycemia (Baseline to Week 4)
Description
Percentage of patients experiencing minor hypoglycemia with a confirmed glucose <54mg/dL
Time Frame
4 Weeks
Title
Episodes of Hypoglycemia (Baseline to Week 4)
Description
Number of episodes of hypoglycemia experienced during the first 4 weeks of the study
Time Frame
4 weeks
Title
Percentage of Patients Experiencing Hypoglycemia (Week 4 to Week 8)
Description
Percentage of patients experiencing minor hypoglycemia with a confirmed glucose <54mg/dL
Time Frame
8 weeks
Title
Episodes of Hypoglycemia (Week 4 to Week 8)
Description
Number of episodes of hypoglycemia experienced between week 4 and week 8 of the study
Time Frame
8 weeks
Title
Percentage of Patients Experiencing Hypoglycemia (Overall)
Description
Percentage of patients experiencing minor hypoglycemia with a confirmed glucose <54mg/dL
Time Frame
4 weeks and 8 weeks
Title
Episodes of Hypoglycemia (Overall)
Description
Number of episodes of hypoglycemia experienced overall during the study
Time Frame
4 weeks and 8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Have type 2 diabetes
Has HbA1c 7.0% to 11.0%, at or within 4 weeks prior to Visit 1.
Have a fasting glucose concentration <280 mg/dL at Visit 1
Have been treated with a stable dose of immediate or extended release metformin for at least 60 days prior to screening OR TZD (rosiglitazone or pioglitazone) for at least 120 days prior to screening.
Are between 18 and 70 years of age, inclusive.
Have body mass index ≥25 kg/m2 and ≤45 kg/m2.
Have a history of stable body weight (not varying by >10% for at least 3 months prior to screening).
Can swallow oral study drug capsule, without splitting or crushing.
Exclusion Criteria:
Female patients of childbearing potential (not surgically sterilized and between menarche and 1 year postmenopause) who meet any of the following criteria:
Are breastfeeding.
Test positive for pregnancy at the time of screening.
Intend to become pregnant during the study.
Have not practiced a reliable method of birth control (for example, use of oral contraceptives or Norplant®; diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam; intrauterine devices; partner with vasectomy; or abstinence) for 3 months prior to screening.
Treated with any of the following medications:
Insulin, exenatide, pramlintide, sulfonylureas or meglitinides within 3 months of screening
Alpha-glucosidase inhibitor within 2 months of screening.
Drugs that directly affect gastrointestinal motility, including, but not limited to metoclopramide, cisapride, and chronic macrolide antibiotics.
Use of a drug for weight loss (for example, prescription drugs such as orlistat, sibutramine, phentermine, or similar over-the-counter medications) within 3 months prior to Visit 1.
Systemic corticosteroids by oral, intravenous, or intramuscular route within 2 months of screening.
Have a history of renal transplantation or are currently receiving renal dialysis.
Have obvious clinical signs or symptoms of liver disease or acute or chronic hepatitis.
Have known active proliferative retinopathy or macular edema expected to need treatment with focal photocoagulation within 3 months.
Have an active or untreated malignancy, or have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years.
Have had organ transplantation.
Have received GLP-1 analogs other than exenatide or DPP-4 inhibitors within the previous 3 months.
Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chief Medical Officer, MD
Organizational Affiliation
Eli Lilly and Company
Official's Role
Study Director
Facility Information:
Facility Name
Research Site
City
San Antonio
State/Province
Texas
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione
We'll reach out to this number within 24 hrs